3/16/2023 0 Comments Syte crunchbase![]() “ This increase in VC funding mirrors national trends, and provides additional capital which will drive continued, significant growth of labs, biomanufacturing, and jobs across the state.” The findings, said the organization, demonstrates continued growth and confidence in Massachusetts’ early-stage R&D cluster.įollowing record-breaking numbers in 2020, 2021 saw an increase of 70% - US$13.66bn in total - in venture capital (VC) funding to Massachusetts-based biopharma companies, it reported. January saw MassBio release its 2021 Massachusetts Biopharma Funding Report. VC investment in Massachusetts biopharma firms up 70% Martin Williams is the CEO and founder of SYTE.bio. The developer aims to deliver novel and effective therapeutics and vaccines enabling precise corrective and preventive treatments for patients worldwide. SYTE.bio is an early-stage synthetic biology company focused on the discovery, development, and future commercialization of precision therapeutics using its proprietary Linear DNA and Circular RNA technology platforms. Shoutian Zhu is its CEO and co-founder, Wenshe Liu is the company’s CSO and another co-founder, while James Schaeffer is CBO and a co-founder as well. It is modality agnostic: its pipeline and technology platforms span small molecules to functionalized peptides and next generation cell therapies. is a biotech startup focused on the discovery and development of therapies for unmet medical needs including oncology, fibrosis, cardiovascular diseases, and infectious diseases. PhenoTarget Biosciences, San Diego, California It says its MARC technology is twice as potent as CAR-T, while reducing side-effects ten-fold, which, the company added, will enable adoptive cell therapy to break-in to new indications in autoimmunity and regenerative medicine.ĭavid Cotnoir-White is the company’s CEO and co-founder, and Étienne Gagnon is its CSO and also co-founder Modulari-T is a preclinical stage immunotherapy startup developing a novel platform, the MARC, to reprogram immune cells for oncology and beyond. Modulari-T Biosciences, Montreal, Canada Jane Lapon is the firm’s CEO, and David Allinson is its CFO and head of business development. ![]() To address this, the startup is developing a kidney-targeted peptide that is designed to prevent regulated cell death and kidney failure. Their initial focus is acute kidney injury (AKI), a condition affecting millions worldwide yet one that still lacks effective treatment approaches. Its technology, developed by the company founders at MIT, combines biocompatible materials, 3D printing of axon mimics, and patient-derived human cells to generate remyelinating drugs for multiple sclerosis.Īnna Jagielska is its president, CEO, CSO and co-founder, while Kavin Kowsari is company vice president, CTO and co-founderĪtorvia Health Technologies, Ottawa, Canada Ītorvia’s purpose is to transform outcomes for patients with severe medical conditions. The line-upĪrtificial Axon Labs, Topsfield, MassachusettsĪrtificial Axon Labs is developing a drug discovery platform aimed at neurodegenerative diseases. The startups were selected following a rigorous vetting and interview process, led by a review board of industry leaders, said MassBio. The companies will also receive a stipend award from Bristol Myers Squibb (BMS) and access to and/or resources from MassBioDrive partners. Over the course of the eight-week program, the selected startups will participate in growth-focused business training taught by seasoned experts, and they will partner with a small, dedicated group of industry mentors. From simplifying CAR-T production to developing new therapeutics for acute kidney injury patients, the MassBioDrive spring cohort has enormous potential to address pressing unmet medical needs,” said Joe Boncore, CEO of MassBio. “The science and technologies that these companies are pioneering represent the future of the life sciences. The initiative, called MassBioDrive, looks to harness the power of the organization’s global life sciences network to help new founders launch their startups more effectively and efficiently. The Massachusetts Biotechnology Council (MassBio) has just revealed the five emerging biotech companies chosen to participate in the spring 2022 cohort of its accelerator program.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |